accessibilityaccreditedactiveactivityaimalarmalign-bottomalign-center-horizontalalign-center-verticalalign-leftalign-rightalign-topanchorangelannoyedapplearchivearrow-downarrow-leftarrow-rightarrow-uparticleat-signawardbalanceballoonbandaidbarcodebellbicyclebinocularsblindboatbook-closedbookbookmarkbookmarkedbooksbottlebriefcasebrushbugbullhornbuscabinetcakecalendarcameracarcashcertificatechalkchart-barschart-linechart-piechatcheckmarkchevron-downchevron-leftchevron-rightchevron-upcircle-arrow-downcircle-arrow-leftcircle-arrow-rightcircle-arrow-upcircle-backwardcircle-checkmarkcircle-chevron-downcircle-chevron-leftcircle-chevron-rightcircle-chevron-upcircle-crosscircle-ejectcircle-exclamationcircle-facebookcircle-firstcircle-forwardcircle-googlepluscircle-gustcircle-lastcircle-linkedincircle-minuscircle-nextcircle-pausecircle-play-thincircle-playcircle-pluscircle-previouscircle-questioncircle-stopcircle-twittercircleclipboard-checkclipboardclockcloud-databasecloud-downloadcloud-fogcloud-gearcloud-lightningcloud-lockcloud-raincloud-snowcloud-synccloud-uploadcloudcocktail-glasscodecombinecomment-fillcommentcommentscompassconfusedconnectconstruction-coneconstructioncontactscoolcopycredit-cardcropcrosscrowncubedatabasedeletedesigndesktopdiamonddicedinnerdisconnectdocumentdownloaddrawerdreamdropletdumbbellearthediteggellipsisenter-downenter-leftenter-rightenter-upenterenvelopeevilexcludeexit-downexit-leftexit-rightexit-upexitexpandeye-droppereyefacebookfactoryfeatherfile-audiofile-codefile-imagefile-videofile-zipfilefilm-playfindfirefirst-aidflagflip-horizontalflip-verticalfloppy-diskfolderfootprintframefunnelgamepadgasgeargiftglassglassesgoogleplusgraduationgrin-evilgringroupgungusthamburgerhammerhappy-grinhappyheadsetheart-fillhearthistoryhomeiconsinboxintersectipadiphonekeykeyboardkeyholeknifelablamplaptopleafleave-downleave-leftleave-rightleave-uplibrarylifebuoylighterlightning-boltlinklinkedinlistlocationlocklotusmadmagicmagnetmalletmanmapmedalmeet-downmeet-leftmeet-rightmeet-upmic-mutemicminusmoonmousemovemusic-notemusicmustachemutenavigationneutralnewsoptionsoutletpaint-rollerpaintbrushpairpaper-planepaperclippaperspastepatchpawpenpencilphonephotopicturepinpine-treeplaneplayplaylistplug-cordpluspodiumpowerpresentationprinterprofilepulsepuzzlequestionquote-closequote-openradiorank1rank2rank3receptionrecycleredorefreshregisterreply-allreplyroad-signrocketrulersadscissorsscreensearchshareshieldshipshirtshockedshrinkshufflesignalsitemapskullsmartphonesmilespeed-fastspeed-mediumspeed-slowspell-checksquaresubtractsunsyncsyringetabtablettagtagstargetteacupterminalthumbs-downthumbs-uptickettilestimertoilet-papertonguetoolstrailertraintransmissiontrashtreetrophytrucktvtwitterumbrellaundounlinkunlockuploaduserusersvolume-highvolume-lowvolume-mediumvolumewarningwheelchairwifiwinkwomanwonderingwrenchzoom-inzoom-out

Invest in Vivid Genomics

Precision medicine to improve the treatment of dementia

  • $345,000Amount raised
  • $5,000Minimum
  • $7,500,000Valuation cap

Purchased securities are not listed on any exchange. A secondary market for these securities does not currently exist and may never develop. You should not purchase these securities with the expectation that one eventually will.

Vivid Genomics is accepting investments for an Offering under Regulation D through SI Securities, LLC ("SI Securities"). SI Securities is an affiliate of SeedInvest Technology, LLC, a registered broker-dealer, and member FINRA/SIPC. SI Securities will receive cash compensation equal to 7.50% of the value of the securities sold and equity compensation equal to 5.00% of the number of securities sold. This profile may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events based on information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they are meant for illustrative purposes and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results.


Company Highlights

  • Using PCT patent pending, machine learning analytical platform to develop non-invasive genetic tests
  • Received letters of interest from multiple therapeutics companies including Roche and Cassava Sciences
  • Finalist for the Xconomy Awards San Diego, selected as one of San Diego Venture group’s "Cool Companies", and graduate of the Creative Destruction Lab program
  • CEO has PhD in Population Genetics from University of Chicago and >10 years business experience including a sell-side equity analyst position and senior marketing strategy roles at Illumina
  • Strategic advisors include genomics industry executives and scientific advisors from leading academic institutions including Stanford, USC, and WashU

Fundraise Highlights

  • Total Amount Raised: US $345,000
  • Total Round Size: US $2,250,000
  • Raise Description:  Pre-Seed
  • Minimum Investment:  US $5,000 per investor
  • Security Type:  Convertible Note
  • Valuation Cap:  US $7,500,000

Our goal is to accelerate and improve dementia drug development using precision medicine. By developing genetic tests, our vision is to identify the right patients for clinical trials to increase the potential for a successful trial.


There are >50M living with Alzheimer's disease, with numbers expected to triple in the next 30 years, yet there are zero disease-modifying drugs approved by the FDA that cure, delay the onset, or slow the advance of disease.  Drug development in Alzheimer's is notorious for failures, with more than 150 failed trials in the last 20 years.  These failures are generally attributed to either the incorrect biology and target of the drug, or because the drug works but has been tested in the wrong patients, at the wrong time, or with the wrong dose.  Patient variation can make it difficult to see whether a drug is truly effective or not.  

We are addressing the problem of patient variation by developing genetic tests to predict and quantify this variation.  With this information, pharma companies are able to better design and analyze clinical trials, which ultimately reduces trial costs, reduces enrollment time, and most importantly to drug developers and to patients, increases the probability that trials and drugs will be successful.  

Our approach is aggregating data from thousands of gold standard samples, running that through our proprietary platform, which allows us to develop highly predictive genetic tests to identify brain characteristics that affect disease but can’t easily be seen.  Our first two tests have strong predictive performance predicting brain plaques (or amyloid plaques, which are one of the diagnostic criteria of Alzheimer's), and identifying individuals with limited cognitive decline.  We have multiple letters of interest from pharma companies, and are in discussion with two companies for pilot studies in Q2-20.  

Media Mentions

The Team

Founders and Officers

Julie’s career has been motivated by the real-world application of genomics, as a sell-side equity analyst covering life science tools and molecular diagnostics companies at Robert W Baird, and in senior marketing strategy roles at Illumina to accelerate the clinical application of genomics in complex diseases by launching commercially available genomic tools and managing KOL collaborations. At Illumina she was responsible for a $600M revenue segment for Complex Disease. Julie holds a BSc from the University of Calgary, and PhD in evolutionary population genetics from the University of Chicago.

Julie Collens, PhD

CEO

Julie’s career has been motivated by the real-world application of genomics, as a sell-side equity analyst covering life science tools and molecular diagnostics companies at Robert W Baird, and in senior marketing strategy roles at Illumina to accelerate the clinical application of genomics in complex diseases by launching commercially available genomic tools and managing KOL collaborations. At Illumina she was responsible for a $600M revenue segment for Complex Disease. Julie holds a BSc from the University of Calgary, and PhD in evolutionary population genetics from the University of Chicago.

Key Team Members

Jared Cara

Data Scientist

Annah Moore, PhD

Data Scientist

Identified

VP Development Operations

Notable Advisors & Investors

Kirk Malloy, PhD

Advisor, Strategic Advisor, Life Sciences and genomics

Ashley Van Zeeland, PhD

Advisor, Strategic Advisor, Commercialization of Analytical tools

Thomas Beach, MD, PhD

Advisor, Scientific Advisor, Neuropathologist

Abraham Palmer, PhD

Advisor, Scientific Advisor, Genomics analysis in large data sets

Adam Butler

Advisor, Strategic Advisor, Business Development for CNS trials

John Sullivan MBA

Advisor, Strategic Advisor, Business strategy

Dennis Wall, PhD

Advisor, Scientific Advisor, Machine learning in Genomics analyses

Lon Schneider MD

Advisor, Scientific Advisor, Dementia clinical trials methods

Ali Torkamani, PhD

Advisor, Scientific Advisor, Genomics analysis and polygenic risk scores

Carlos Cruchaga, PhD

Advisor, Scientific Advisor, Alzheimer's disease genomics

Investor Perks

$25k

Invite to quarterly company update webinar for investors

$100k

All of the above plus a private meeting and dinner with management team

$250k

All of the above plus a board observer seat

It is advised that you consult a tax professional to fully understand any potential tax implications of receiving investor perks before making an investment.

Frequently Asked Questions

Making an Investment in Vivid Genomics
How does investing work?

When you complete your investment on SeedInvest, your money will be transferred to an escrow account where an independent escrow agent will watch over your investment until it is accepted by Vivid Genomics. Once Vivid Genomics accepts your investment, and certain regulatory procedures are completed, your money will be transferred from the escrow account to Vivid Genomics in exchange for your securities. At that point, you will be a proud owner in Vivid Genomics.


What is the difference between preferred equity and a convertible note?

Preferred equity is usually issued to outside investors and carries rights and conditions that are different from that of common stock. For example, preferred equity may include rights that prevent or minimize the effects of dilution or grants special privileges in situations when the company is sold.

A convertible note is a unique form of debt that converts into equity, usually in conjunction with a future financing round. The investor effectively loans money to a startup with the expectation that they will receive equity in the company in the future at a discounted price per share when the company raises its next round of financing.

To learn more about startup investment types check out “How to Choose a Startup Investment” in our academy.


What will I need to complete my investment?

To make an investment, you will need the following information readily available:

  1. Personal information such as your current address and phone number
  2. Employment and employer information
  3. Net worth and income information
  4. Social Security Number or passport
  5. ABA bank routing number and checking account number (typically found on a personal check or bank statement)

Because Vivid Genomics is offering its securities under Rule 506(c) of Regulation D, your status as an Accredited Investor will also need to be verified and you will be asked to provide documentation supporting your income, net worth, revenue, or net assets or a letter from a qualified advisor such as a Registered Investment Advisor, Registered Broker Dealer, Lawyer, or CPA.


What if I change my mind about investing?

Until a closing occurs, you may cancel your investment at any time, for any reason. You will receive an email when the closing occurs and your securities have been issued. If you have already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To cancel your investment, please go to your portfolio page by clicking your profile icon in the top right corner.


After My Investment
How can I sell my securities in the future?

Currently there is no market or liquidity for these securities. Right now Vivid Genomics does not plan to list these securities on a national exchange or another secondary market. At some point Vivid Genomics may choose to do so, but until then you should plan to hold your investment for a significant period of time before a “liquidation event” occurs. A “liquidation event” is when Vivid Genomics either lists their securities on an exchange, is acquired, or goes bankrupt.


How do I keep track of this investment?

You can return to SeedInvest at any time to view your portfolio of investments and obtain a summary statement.


Other General Questions
What is this page about?

This is Vivid Genomics's fundraising profile page, where you can find information that may be helpful for you to make an investment decision in their company. The information on this page includes the company overview, team bios, and the risks and disclosures related to this investment opportunity.


What are the risks of this investment?

This investment is highly speculative and should not be made by anyone who cannot afford to risk the entire investment amount. In addition to these risks, you should carefully consider the specific information and risks disclosed in Vivid Genomics’s profile.